Browsing Category

63502 posts
FriendliAI Unveils Serverless Endpoints for Widespread, Affordable Access to Open-source Generative AI Models

FriendliAI Unveils Serverless Endpoints for Widespread, Affordable Access to Open-source Generative AI Models

REDWOOD CITY, Calif., Jan. 4, 2024 /PRNewswire/ — FriendliAI, a leader in…
LILYSILK Celebrates Two-Year Partnership with TerraCycle®, Empowering Sustainable Consumption

LILYSILK Celebrates Two-Year Partnership with TerraCycle®, Empowering Sustainable Consumption

NEW YORK, Jan. 4, 2024 /PRNewswire/ — LILYSILK, the world’s leading silk…
XREAL Ships Industry-Leading 350,000 AR Glasses, Takes 51% of Worldwide AR Market in Q3 2023

XREAL Ships Industry-Leading 350,000 AR Glasses, Takes 51% of Worldwide AR Market in Q3 2023

Showing strong momentum and brand growth, XREAL secures a dominant position in…
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Jan. 4, 2024 /PRNewswire/ — JW Therapeutics (HKEx: 2126), an independent and innovative…
Award Winners of the Singapore SME 500 Award 2023 Recognised at ATC's inaugural SMESummit

Award Winners of the Singapore SME 500 Award 2023 Recognised at ATC's inaugural SMESummit

SINGAPORE, Jan. 4, 2024 /PRNewswire/ — The Singapore SME 500 Award 2023 presentation…
Bangkok Bank increases deposit and loan interest rates with Thai economy is expected to continue…

Bangkok Bank increases deposit and loan interest rates with Thai economy is expected to continue…

Bangkok Bank is raising both deposit and loan interest rates with Thai…
Former Tech Mahindra CEO C.P. Gurnani joins upGrad's Board of Directors

Former Tech Mahindra CEO C.P. Gurnani joins upGrad's Board of Directors

NEW YORK, Jan. 4, 2024 /PRNewswire/ — upGrad, one of Asia’s largest…
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

– AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile –…